BACKGROUND: Intrahepatic recurrence is a major problem after curative resection of hepatocellular carcinoma. However, the most effective treatments for patients with intrahepatic recurrence still remain unclear. In addition, the selection of various treatment modalities such as repeat resection, local ablation therapy, and transarterial chemoembolization is only applicable to patients with intrahepatic nodular recurrence. METHODS: Of 353 patients who underwent curative resection, 97 patients with intrahepatic nodular recurrence were retrospectively studied. The prognostic factors for survival after recurrence and treatment modalities were analyzed. The patients were divided into two groups, a control group and a progression group, according to their response to initial treatment for recurrent tumors. RESULTS: The 1-, 3-, and 5-year overall survival rates after recurrence in patients with intrahepatic nodular recurrence were 91.0%, 71.0%, and 37.5%, respectively. Multivariate analysis revealed that early recurrence (< or =12 months), Child-Pugh class B or C at diagnosis of recurrence, and serum albumin level of < or =3.5 g/dL at diagnosis of recurrence were poor prognostic factors for survival after recurrence. With regard to the response to the initial treatment, time to recurrence of < or =12 months was found to be the only statistically significant risk factor for progression of disease in multivariate analysis. CONCLUSIONS: Time to recurrence, which usually corresponds with the cellular origin of recurrence, seems to be more important when determining the prognosis of patients with recurrent disease and treatment response than treatment modality. Therefore, different treatment methods should be selected according to the time to recurrence of intrahepatic nodular recurrence.
BACKGROUND: Intrahepatic recurrence is a major problem after curative resection of hepatocellular carcinoma. However, the most effective treatments for patients with intrahepatic recurrence still remain unclear. In addition, the selection of various treatment modalities such as repeat resection, local ablation therapy, and transarterial chemoembolization is only applicable to patients with intrahepatic nodular recurrence. METHODS: Of 353 patients who underwent curative resection, 97 patients with intrahepatic nodular recurrence were retrospectively studied. The prognostic factors for survival after recurrence and treatment modalities were analyzed. The patients were divided into two groups, a control group and a progression group, according to their response to initial treatment for recurrent tumors. RESULTS: The 1-, 3-, and 5-year overall survival rates after recurrence in patients with intrahepatic nodular recurrence were 91.0%, 71.0%, and 37.5%, respectively. Multivariate analysis revealed that early recurrence (< or =12 months), Child-Pugh class B or C at diagnosis of recurrence, and serum albumin level of < or =3.5 g/dL at diagnosis of recurrence were poor prognostic factors for survival after recurrence. With regard to the response to the initial treatment, time to recurrence of < or =12 months was found to be the only statistically significant risk factor for progression of disease in multivariate analysis. CONCLUSIONS: Time to recurrence, which usually corresponds with the cellular origin of recurrence, seems to be more important when determining the prognosis of patients with recurrent disease and treatment response than treatment modality. Therefore, different treatment methods should be selected according to the time to recurrence of intrahepatic nodular recurrence.
Authors: Jin Hong Lim; Gi Hong Choi; Sung Hoon Choi; Hyung Soon Lee; Kyung Sik Kim; Jin Sub Choi Journal: World J Surg Date: 2015-04 Impact factor: 3.352
Authors: Peng S Koh; Albert C Y Chan; Tan T Cheung; Kenneth S H Chok; Wing C Dai; Ronnie T P Poon; Chung M Lo Journal: HPB (Oxford) Date: 2016-01 Impact factor: 3.647